BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

I noticed in Simes interview he was still holding back on the CV Risk reduction benefit today. Though he stressed the 5 years of proven safety for testosterone use for women, he left out the most important benefit. Following the FDA meetings, we will probably get a PR. I wonder if they will do the same as the did with Libigel, and commission an independent survey of cardiologists and family physicians to identify an estimated commitment for adoption of Libigel for the CV benefit. This will give us more accurate revenue potential and value (ie, partnership, etc..). It also demonstrates due diligence in estimating future revenue and provides a good defense against frivolous lawsuits.